Active Biotech Ab

Pharmacyl Ab

Anders Björk

Karl Erik Jansson

Gunnar Hedlund

Tomas Fristedt

Hans Wännman

A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use in combination with a 5-ASA agent, in the treatment of a disease resulting from pathologic inflammation. The combination of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and 5-ASA agent and use of such combination. A kit-of-parts and a pharmaceutical composition comprising such a combination.

Medical treatment for pathologic inflammation

A method for the treatment a disease resulting from spondyloarthritis, such as axial spondyloarthritis, psoriatic arthritis and enteropathic arthritis, by administering, to a mammal in need of such treatment, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

Treatment of spondyloarthritis

A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; andat least one pharmaceutical excipient;said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

Crystalline salts of quinoline compounds and methods for preparing them

A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II)  A crystalline salt of formula (II) and a process for preparing said salt.

Compositions containing quinoline compounds

A compound of formula (I) wherein A pharmaceutical composition comprising a compound of formula (I), a method of treating malignant tumours or diseases resulting from autoimmunity or pathologic inflammation.

Growing community of inventors

Bjärred, Sweden

Anders Björk